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Abstract 
The cyclization of anticancer drugs into active intermediates has been reported mainly for 
DNA alkylating molecules including nitrosoureas. We previously defined the original 
cytotoxic mechanism of anticancerous N-phenyl N’(2-chloroethyl)ureas (CEUs) that involves 
their reactivity towards cellular proteins and not against DNA; two CEUs subsets have been 
shown to alkylate -tubulin and prohibitin leading to inhibition of cell proliferation by G2/M 
or G1/S cell cycle arrest. In this study, we demonstrated that cyclic derivatives of CEUs, N-
phenyl-4,5-dihydrooxazol-2-amines (Oxas) are two to threefold more active than CEUs and 
share the same cytotoxic properties in B16F0 melanoma cells. Moreover, the CEU original 
covalent binding by an ester linkage on -tubulin Glu198 and prohibitin Asp40 was 
maintained with Oxas. Surprisingly, we observed that Oxas were spontaneously formed from 
CEUs in the cell culture medium and were also detected within the cells. Our results suggest 
that the intramolecular cyclization of CEUs leads to active Oxas that should then be 
considered as the key intermediates for protein alkylation. These results could be useful for 
the design of new prodrugs for cancer chemotherapy.  
 
Keywords: N-phenyl N’(2-chloroethyl)ureas, N-phenyl-4,5-dihydrooxazol-2-amines, -
tubulin, prohibitin, alkylation, cyclization 
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1. Introduction 
A major challenge for improving cancer chemotherapy is to design and synthesize new 
drugs that can selectively target cancer cells and bypass cancer chemoresistance systems. In 
this context, we have developed protein alkylating agents referred to as N-phenyl-N’-(2-
chloroethyl)ureas (CEUs) [1, 2]. Two CEU subsets have been shown to selectively alkylate 
proteins through a unique ester linkage involving Glu198 on -tubulin and Asp40 on 
prohibitin [3, 4]. Both proteins are strongly involved in the regulation of cell growth and cell 
cycle progression [5, 6]. Tubulins are classical targets for antimitotic drugs such as colchicine, 
vinblastine and paclitaxel [7] blocking the G2/M transition of the cell cycle. Prohibitin, a 
chaperon protein involved in gene expression, regulates cell cycle and apoptosis, and has been 
considered as a tumor suppressor [5, 8]. However, no consensus for prohibitin function has 
been established since prohibitin is also required for prim ry and cancer cell proliferation [9, 
10]. The decreased G1/S transition in CEU treated cells, associated with prohibitin alkylation 
is not fully understood and could be linked to either a mitochondrial dysfunction [11] or a 
nuclear repression of E2F1-mediated transcription [12]. -tubulin alkylating CEUs induce a 
G2/M arrest and have obvious antimitotic effects on different types of tumors both in vitro and 
in vivo [13-17]. Hence; the molecular events underlying CEU antiproliferative activity rely on 
the functionality of the targeted protein [3].  
The requirement of the chlorine atom in the CEU -tubulin alkylation mechanism was 
clearly established using conventional structure-activity relationship (SAR) studies showing 
that N-phenyl-N’-ethyl ureas were devoid of cytotoxicity and unable to alkylate -tubulin [1]. 
Recently, we unexpectedly found that N-phenyl-4,5-dihydrooxazol-2-amines (Oxas) were 
more active than their CEU counterparts and still alkylating -tubulin as demonstrated by 
western blot analysis [18]. It has been reported previously that the presence of oxazolinic 
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heterocycles improves the efficiency of molecules developed for pancreatic cancer treatment 
[19] as well as of drugs inhibiting angiogenesis [20]. 
Here, we have determined the cytotoxicity mechanisms of three different Oxas and 
characterize their covalent binding to target proteins in B16F0 melanoma cells at the 
molecular level. Our results clearly showed that Oxas and their parent CEUs have the same -
tubulin and prohibitin amino acid targets. We further observed, for the first time, that the 
cyclization of CEUs into Oxas occurs spontaneously in the culture medium and that these Oxa 
forms were present within the cells. These data suggest that Oxas could be the reactive 
intermediates of CEUs.  
 
2. Material and methods  
2.1 Chemicals  
N-(4-iodophenyl)-N’-(2-chloroethyl)urea (ICEU), N-(4-iodophenyl)-4,5-dihydrooxazol-2-
amine (IOxa), N-(4-tertbutylphenyl)-N’-(2-chloroethyl)urea (tBCEU), N-(4-tertbutylphenyl)-
4,5-dihydrooxazol-2-amine (tBOxa), N-(4-cyclohexylphenyl)-N’-(2-chloroethyl)urea 
(cHCEU), N-(4-cyclohexylphenyl)-4,5-dihydrooxazol-2-amine (cHOxa) were synthesized as 
previously described [21, 22]. All compounds were dissolved in DMSO at a concentration of 
40 mM and stored at -20°C. The experiments were all performed with a final concentration of 
0.5% DMSO in culture medium. 
2.2 Cell culture 
B16F0 murine melanoma cell line was purchased from the American Type Culture Collection 
(Manassas, VA, USA). Cells were cultured in DMEM (Invitrogen, Cergy-Pontoise, France) 
supplemented with 10% fetal bovine serum (Biowest, Paris, France), 1 mM non-essential 
amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen), and 4 μg/mL gentamicin 
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(Invitrogen). The cells were maintained at 37 ºC in a moisture-saturated atmosphere 
containing 5% CO2.  
2.3 Antiproliferative activity 
Cell cytotoxicity was assessed using the resazurin assay as previously described [23]. To 
determine growth inhibitory concentrations, which is the concentration of the drug required to 
inhibit 50% of the tumor cell growth (GI50), 3.5 x 10
3
 B16F0 cells were seeded into 96-well 
microtiter plates (NunclonTM, Nunc, Roskilde, Denmark) and maintained at 37°C in a 
moisture-saturated atmosphere containing 5% CO2 for 24 hours and then incubated with 
escalating drug concentrations (1-50 µM) for 48 hours. Fluorescence (excitation/emission: 
530/590 nm) was measured with a microtiter plate fluorescence reader (Fluoroskan Ascent 
FL, Thermo Labsystems, Helsinki, Finland). 
2.4 Cell cycle progression analysis - flow cytometry 
Cell cycle progression was analysed by flow cytometry with propidium iodide staining as 
previously described [3].  
2.5 Determination -tubulin and prohibitin alkylation by western blot analysis 
-tubulin alkylation was determined by immunobloting. Briefly, B16F0 cells were harvested 
from 60 mm Petri dishes (6X 10
5 
cells/dish), proteins were extracted in RIPA buffer with 
EDTA-free protease inhibitor cocktail (Roche Diagnostics, Meylan, France). Protein 
concentration was determined by Bradford assay using a CooAssay Protein Determination Kit 
(Interchim, Montluçon, France). For -tubulin alkylation, fifty µg of total protein were 
separated on 10% SDS-polyacrylamide gels. For prohibitin alkylation, one hundred µg of urea 
extracted proteins (see 2DE paragraph) were submitted to IEF on 7-cm IPG strips pH 3 to 10 
(BioRad, Hercules, CA, USA) at 8000V/h, followed by a 12% SDS-polyacrylamide gel 
electrophoresis. Gels were transferred onto nitrocellulose membranes (Immobilon NC; 
Millipore, St-Quentin-en-Yvelines, France). The membranes were blocked in 5% non-fat dry 
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milk in TBS-T (0.1% Tween 20) buffer and the blots were then incubated with a monoclonal 
anti-β-tubulin antibody (Anti TUB2.1; Sigma, St-Quentin Fallavier, France) or a monoclonal 
anti-prohibitin antibody (Abcam, Paris, France), then probed with anti-mouse horseradish 
peroxidase (HRP) conjugated secondary antibody (Dako, Glostrup, Denmark). The blot 
signals were detected by chemiluminescence (ECL, Amersham GE Healthcare, 
Buckinghamshire, UK).  
2.5 Microtubule structure – immunofluorescence 
B16F0 cells were seeded in 8-well culture glass slides (BD Biosciences, Erembodegem, 
Belgium) at a density of 1 X 10
5
 cells/ml for 24 hours. Cells were then treated with 0.5- to 1-
fold GI50 corresponding to 10 µM ICEU, 3 µM IOxa, 8 µM tBCEU, 8 µM tBOxa, 10 µM 
cHCEU or 5 µM cHOxa in vehicle (0.5% DMSO) for 24 hours. They were washed twice with 
PBS and fixed in methanol for 10 min at -20°C. Non-specific sites are blocked using 5% goat 
serum for 30 min. Cells were incubated in 1/1000 diluted mouse monoclonal anti--tubulin 
IgG (Sigma-Aldrich, St. Louis, MO, USA) for 2 hours at room temperature before incubating 
with anti-mouse IgG labelled with Alexa Fluor 488 (Invitrogen) for 1 hour. Slides were 
washed in PBS and then incubated in 10 µg/ml Hoechst 33342 for 5 min to visualize the 
nuclei. Microtubules and nuclei were observed with a fluorescent microscope (Olympus, 
Center Valley, PA, USA) using FITC and DAPI filter sets, respectively. 
2.6 Two-dimensional electrophoresis (2DE) 
For analysis of -tubulin or prohibitin alkylation, two-dimensional electrophoresis was 
conducted as described by Bouchon et al. [4].  
2.7 Mass spectrometry analyses of protein digests 
MALDI-TOF MS analyses were performed according to the published procedure on trypsin 
digests [4] on a Voyager-DE Pro mass spectrometer (ABSciex, Les Ulis, France). 
MALDI/PSD analysis was performed to characterize CEU binding on prohibitin [3]. 
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Nano ESI-MS/MS was used to localize and characterize -tubulin alkylation. Analyses 
were performed essentially as described previously [4] by direct infusion of the peptide 
digest. The MS/MS data from the non-alkylated and alkylated peptides were interpreted 
manually, assuming the modified masses. Fragments are assigned according to the 
nomenclature of Roepstorff and Fohlman [24]. 
2.8 Stability and cellular uptake of drugs - HPLC 
Stability and cellular uptake in B16F0 cells was determined by HPLC. Cells were seeded in 
100 mm Petri dishes (2.10
6 
cells/dish) and cultured for 24 hours. They were then exposed to 
5- to 10-fold GI50 concentration of drugs i.e. 100 µM (1 µmol) ICEU, 30 µM (0.3 µmol) IOxa, 
80 µM (0.8 µmol) tBCEU, 80 µM (0.8 µmol) tBOxa, 100 µM (1 µmol) cHCEU, 25 µM (0.25 
µmol) cHOxa in 0.5% DMSO in Opti-MEM medium supplemented with CaCl2 for 24 hours 
(T24). Culture medium aliquots were collected in the presence or absence of cells, extracted 
with 1 volume 0.2% trifluoroacetic acid (TFA) in acetonitrile (ACN) and centrifuged at 
13000xg for 5 min. For cell lysates, cells were rinsed three times using PBS, scraped, 
centrifuged at 800xg for 10 min and the pellets were stored at -80°C. Free-intracellular drugs 
were then extracted in 0.1% TFA in ACN /H2O (V/V) and this solution was further frozen, 
thawed and sonicated for 15 min. This cycle was repeated twice. After centrifugation at 
13000xg for 5 min, cellular extracts and previously prepared culture media were analysed on 
a HP 1100 series Agilent HPLC (Agilent, Les Ulis, France) equipped with diode array 
detector using a Kromasil 5µ particles C18 column (Interchim, Montluçon, France) at a flow 
rate of 0.4 mL/min. The gradient used was: 0-3 min: 0.1% TFA/40% ACN in H2O; 3-13 min; 
linear gradient to 0.1% TFA/100% ACN; 13-23 min 0.1% TFA/100% ACN. The column was 
reequilibrated after each run for 10 min. Drug concentration was assessed at 255 nm and 
calculated by the peak area compared to standard calibration curve. Each UV peak obtained in 
HPLC was monitored at least once by ESI-MS/MS to confirm the structure of the product.  
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3. Results 
3.1 Antiproliferative and alkylating properties of CEUs and Oxas in B16F0 melanoma 
cells  
Both CEUs and Oxas exhibited antiproliferative activity in the micro molar range (3-17 µM) 
with GI50 being lower for Oxas when compared to the respective CEUs (Table 1). Similarly 
to their CEU counterparts, IOxa and tBOxa induced a cell cycle arrest at the G2/M transition 
while cHOxa lead to G1/S arrest with 90% of cells accumulated in G0/G1 phase 
(Supplementary Figure 1). On western blots, both CEU/IOxa and tBCEU/tBOxa induced 
modification of -tubulin migration, which was split into two bands suggesting protein 
alkylation (Table 1). Incubation of cells with cHCEU/cHOxa changed the pI of prohibitin, 
indicating its alkylation (Table 1). -tubulin alkylating agents such as ICEU, IOxa, tBCEU 
and tBOxa altered microtubule structure as compared to control conditions. 
Immunofluorescent staining showed disorganization of the cytoskeleton architecture and the 
presence of punctuated tubulin aggregates that were not observed in controls (Table 1).  
3.2 Oxas alkylate -tubulin and prohibitin on the same amino acids as CEUs 
The presence of two-tubulin bands after SDS-PAGE of proteins extracted from B16F0 cells 
treated with IOxa and tBOxa (Table 1) suggested that the drugs bound covalently to the 
protein. To characterize the site of interaction, MS analyses were performed on -tubulin 
treated respectively with ICEU, IOxa, tBCEU, tBOxa (Figure 1A). Alkylated tubulin spots 
isolated from 2DE gels were digested by trypsin and analyzed using MALDI-TOF-MS as 
previously described [4]. The native -tubulin peptide [Val175-Arg213] on which alkylation 
had been shown to occur had an apparent molecular weight of 4595.7 (Figure 1A), while the 
peptide alkylated by ICEU presented a m of 288, as already observed [4]. The same m/z 
shift was observed on tubulin extracted from cells treated with IOxa (Figure 1A). To localize 
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the alkylation site, a nano ESI-MS/MS analysis was performed on this modified peptide 
(Figure. 1B). The fragmentation pattern allowed localizing the urea derivative on Glu24 of 
the analyzed peptidecorresponding to-tubulin Glu198 (Figure 1C), as previously shown for 
ICEU itself [4]. An intense fragmentation (m/z 1546.4, Figure 1B) occurred at the peptide-
like bond of the urea chain bound to Glu198 thus demonstrating the linearity of the added 
structure (Figure 1D). 
The same approach was used for tBCEU and tBOxa. For both drugs a m/z shift corresponding 
to the addition of the tBurea derivative was observed (m = 218) indicating alkylation on the 
same [175-213]-tubulin peptide (Figure 1A).  
Prohibitin alkylation was determined using prohibitin spots isolated from 2DE gels (Figure 
2A). When cHCEU is bound to its target, prohibitin exhibits a modified pI, as compared to the 
native protein [3]. The m/z = 720 corresponding to prohibitin peptide [Ala36-Arg41] 
observed in the native protein of control cells was shifted in cHCEU- and cHOxa- treated 
cells to m/z = 964 (Figure 2B). The two modified peptides were further characterized by 
MALDI-PSD analysis (Figure 2C). Their fragmentation patterns were identical in cHCEU 
and cHOxa treated cells, and revealed a modification on Asp5 of this peptide, corresponding 
to Asp40 of the protein. 
3.3 CEU and Oxa stability in culture medium and uptake in B16F0 cells  
ICEU/IOxa, tBCEU/tBOxa and cHCEU/cHOxa were separated by HPLC analysis and 
exhibited retention times of 12.9/4.3 min, 14.2/6.3 min and 16.2/9.8 min, respectively (Figure 
3A). CEUs were spontaneously transformed into Oxas, which remained stable for 24 hours in 
culture media in presence (T24+) or in absence (T24-) of cells (Figure 3B, Table 2). All the 
labelled peaks were recovered and analyzed by MS to confirm the identity. The HPLC 
protocol allowed the recovery of 70 to 98 % of the parent molecules incubated for 24 hours in 
the cell culture medium without cells (Table 2). Using the same HPLC conditions in the 
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presence of cells, the percentage of detected molecules in the medium was lower suggesting 
an uptake of 7.4 to 36.5 % of CEUs and/or Oxas by B16F0 cells (Table 2). However, the 
levels of the intracellular free drug were low (<10%) suggesting that the major part of CEUs 
and Oxas was bound to proteins or biomolecules [25]. Drugs embedded in the cellular 
membranes and/or covalently bound to proteins were not detected by this procedure 
optimized to recover the free compounds. Another possibility was the metabolism of these 
drugs as our analyses were focused only on CEU and Oxa detection. We can also observe that 
the percentage of spontaneous CEU cyclization into Oxa was dependent on the molecular 
structure of the drug (6%, 26 % and 49% for cHOxa, IOxa and tBOxa formation, respectively 
(T24-) (Table 2). 
4. Discussion 
The study of the alkylating properties of CEU represents an interesting field of research 
since xenobiotics able to bind covalently to cellular proteins are relatively uncommon, 
especially when generating ester linkages with acidic amino acids such as glutamic and 
aspartic acids [3]. Here, we have demonstrated that Oxa derivatives are covalently linked to 
the same proteins and the same amino acids as their parent CEUs notably Glu198 for -
tubulin and Asp40 for prohibitin (Figure 1 and 2). CEUs and Oxas exhibited the same 
antiproliferative properties (cell cycle arrest, microtubule disruption specifically for 
antimitotics) (Table 1, Sup Figure 1), however, Oxas were, more active than their CEU 
counterparts. Altogether, these data suggest that both CEUs and Oxas exert their cytocidal 
activity through similar mechanisms and that the pharmacological effects of CEUs could be 
linked to their intramolecular cyclization into Oxas.  
Due to the absence of differences in the molecular masses of -tubulin or prohibitin 
adducts obtained either with CEUs or their corresponding Oxas, we could not determine 
which molecule was involved in the alkylation reaction. However, fragmentation of the 
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modified peptide allowed to show that bound Oxa had a linear structure (Figure 1 and 2). 
Moreover, in culture media CEUs were spontaneously transformed into Oxas. The level of 
these spontaneously formed Oxas in the medium in presence or in absence of cells was 
similar, unlike the concentration of CEUs that was decreased in the presence of cells 
suggesting that CEUs can go through the membranes more easily than Oxas, even if they 
display quite similar logP value (data form ALOGPS (http://www.vcclab.org/lab/alogps/, data 
not shown). However, the Oxa level in the culture medium for IOxa-, tBOxa- and cHOxa-
treated cells was reduced compared to that without cells (26%, 10% and 33%, respectively) 
showing that Oxas can penetrate into the cells. The low presence of free Oxas in cells and 
their higher antiproliferative index (GI50) strongly suggest that Oxas are significantly more 
reactive with biomolecules than CEUs.  
The chlorine atom being necessary to maintain CEU -tubulin capacity to alkylate proteins 
[1], we can speculate that cyclization of CEUs into Oxas required this atom to confer electro-
attractor property. This cyclization step could involve the formation of a carbocation and/or 
an aziridinic intermediate (Figure 4) as recent studies demonstrated that N-acyl-2,2-
dimethylaziridines could evolve into oxazolinic forms [26]. These two potential intermediates 
characterized by very short half-lifes, are difficult to observe in a biological context but it is 
established that the aziridinium structures were clearly involved in DNA alkylation by N-
nitrosoureas and nitrogen mustards [27]. Interactions between -tubulin and CEUs were 
studied using CoMFA and CoMSIA models [28]. From these studies, it was deduced that the 
ethylene chloride group of CEU was essential for the alkylation of Glu198 and that the 
stabilization of a complex involving the colchicine-binding site and the CEU preceded the 
completion of the Glu198 alkylation [29]. This intermediate complex should involve the 
stabilizing contribution of Cys239 among other amino acids [29]. We are unable to conclude 
if antimitotic CEUs are transformed into oxazolines in the colchicine-binding site of -
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tubulin, when the urea group interacting with Cys239 [29] stabilizes the molecules, or react 
spontaneously with acidic amino acids in a nucleophilic substitution reaction. Recent SAR 
studies modifying the urea moiety of CEUs indicates that only 2-chloroacetamides and 2-
chloroacetylureas retained the cytotoxic properties without -tubulin alkylation [30]. In these 
two series of molecules, the CEU cyclization into Oxa could not occur reinforcing the 
hypothesis that cyclization might be necessary for -tubulin alkylation. 
New CEUs will be synthesized to elucidate this interesting point concerning the alkylation 
process of Glu and Asp residues and to enhance our knowledge about the specific interactions 
occurring in the colchicine-binding site. From a biological point of view, previous in vivo data 
did not allow detecting oxazolinic forms or dechlorinated CEUs in urines of mice treated with 
tBCEU, [31] while some unidentified metabolites were found in blood, tumors and colon of 
mice treated with ICEU [32]. In vivo investigations will be pursued to identify these 
metabolites and to determine precisely the active forms of CEUs or Oxas. 
In conclusion, one difficulty of this study was the absence of a mass difference between the 
CEU or Oxa protein adducts revealed by mass spectrometry analyses, another one was based 
on the fact that N-phenyl N’(2-chloroethyl)ureas cyclised spontaneously in cell culture 
medium. However, we demonstrated that Oxas had similar mechanisms of cell cytotoxicity 
and were present in the cells treated with CEU derivatives. We therefore suggest that Oxas 
constitute key structures for the alkylation of cellular proteins. This study confers new 
insights for drug conception through the cyclization of chlorinated forms into more active 
oxazolinic ones. 
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Figure Legends 
Figure 1  
-tubulin alkylation by CEUs and their corresponding Oxas. (A) Comparative analyses by 
MALDI-TOF-MS of tubulin high mass peptides obtained in tubulin tryptic digest after 
DMSO treatment of cells or after ICEU, IOxa, tBCEU or tBOxa treatment. The low peak 
intensity observed in the case of ICEU was a partial dealkylation before analysis due to 
alkaline conditions during trypsin digestion. (B) ESI-MS/MS spectrum of the alkylated 
peptide obtained by IOxa. (C) Fragmentation pattern along the peptidic chain with 
localization of the alkylated amino acid on E23 of this peptide. (D) Fragmentation pattern in 
the bound structure confirming the opening of the oxazolinic heterocycle and its resulting 
linear structure. Z stands for the bound oxazoline derivative, whose structure is developed in 
scheme D with a grey background. Z* corresponds to a fragmentation along the bound 
structure, as indicated on the scheme. °, loss of one water molecule. 
Figure 2  
Prohibitin alkylation by cHCEU and its corresponding cHOxa. (A) Prohibitin spots 
localized on 2D gels  (B) MALDI-TOF-MS analysis of these spots (C) Fragmentation spectra 
obtained from the two peptides  having a m/z 964  (D) Fragmentation of peptide [AVIFDR], 
D being alkylated by a cyclo-hexyl-phenyl urea. The bound developed cyclohexyl structure is 
shown with a grey background to localize M* and M** fragments along the urea chain. “b” 
and “y” fragments were obtained from N and C-terminal fragmentation, respectively. 
 
Figure 3 
Quantitative HPLC analysis of ICEU, tBCEU or cHCEU in B16F0 cells. (A) Analysis of 
standard compounds (B) Analysis of cell culture medium after 24 hours of ICEU, tBCEU or 
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cHCEU exposure in absence (T24-) or presence (T24+) of B16F0 cells (C) Analysis of cell 
lysates obtained from B16F0 cells cultured for 24 hours in serum-free Opti-MEM medium 
(T24+c) in the presence of 100 µM ICEU, 80 µM tBCEU or 100 µM cHCEU. White arrows 
indicate CEUs, black arrows Oxas. 
Figure 4 
Scheme of the putative mechanisms leading to CEU cyclization into Oxas and reactivity 
of the protagonists with proteins. CEUs, Oxas and their intermediates could react with 
acidic part of Glu/Asp residues of target proteins. 
 
Supplementary Figures  
Figure 1 
ICEU/IOxa and tBCEU/tBOxa block B16F0 cell cycle at G2/M and cHCEU/cHOxa at 
G1/S transitions. Distribution of cells in different cell-cycle phases is expressed as the 
percentage of total cell number. Dotted lines indicate the percentage of each phase in control 
cells. 
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Table 1. Anti-proliferative and alkylating properties of CEUs and Oxas on B16F0 melanoma 
cells. 
Compound Structure 
GI50 
(μM) 
-tubulin 
alkylation 
Microtubule 
structure 
DMSO 
 
  
  
ICEU 
N-(4-iodophenyl)- 
N’-(2-chloroethyl)urea 
 
10.6   
IOxa 
N-(4-iodophenyl)- 
4,5-dihydrooxazol-2-
amine 
 
2.9  
 
tBCEU 
N-(4-tertbutylphenyl)- 
N’-(2-chloroethyl)urea 
 
13.1 
  
tBOxa 
N-(4-tertbutylphenyl)- 4,5-
dihydrooxazol-2-amine 
 
7.1 
 
 
Compound Structure GI50 Prohibitin alkylation 
cHCEU 
N-(4-cyclohexylphenyl)- 
N’-(2-chloroethyl)urea 
 
17.0 
 
 
cHOxa 
N-(4-cyclohexylphenyl)- 
4,5-dihydrooxazol-2-
amine 
 
7.2   
GI50: drug concentration inhibiting 50% of cell growth; -tubulin alkylation: determined by 
western blot in B16F0 cells treated or not (DMSO) for 24 hours at 5-10 x GI50 drug 
concentration; Microtubule structure: visualised by immunofluorescence in B16F0 cells 
P
ro
h
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it
in
 a
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y
la
ti
o
n
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* 
* 
* 
* 
DMSO 
cHCEU 
cHOxa 
* 
* 
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treated or not (DMSO) for 24 hours at one GI50 drug concentration; prohibitin alkylation: 
determined by 2D western blot in B16F0 cells treated or not for 24 hours at a 5-10 x GI50 drug 
concentration. Arrows indicate the native form of the protein, asterisks indicate the alkylated 
form of the protein. 
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Table 2. Drug recovery in culture medium and in B16F0 cells.  
 
Drug 
treatment 
Drug recovery  
in culture medium (%) 
 
 Drug recovery  
in cell lysates (%) 
Calculated 
Drug content in cell 
pellets (%) 
 T24- T24+  T24+ T24+ 
 CEU Oxa CEU Oxa  CEU Oxa CEU and Oxa 
          
ICEU  71.7 25.9 40.9 24.1  3.7  0.35 28.55 
IOxa  - 95.1 - 68.7  - 1.0 25.4 
tBCEU   34.0  48.6  24.5  50.4  nd  0.29 7.41 
tBOxa  -  90.0 - 80.0  -  0.45 9.55 
cHCEU   82.8  6.0  36.1  5.9   7.3  3.0 36.5 
cHOxa  -  72.3 - 39.4  -  5.3 27.6 
nd: not detected; - :not applicable 
Concentrations of each compound were determined by HPLC and expressed as the percentages of the initial drug input. The culture medium was 
collected after 24 hours of incubation in the absence (T24-) or presence of cells (T24+). Drug recovery in cell pellets was calculated from drug 
recovery in other compartments and reported to the maximal amount of drugs recovered without cells (T24-). The values represent the mean of at 
least 2 independent experiments. 
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Table 1. Anti-proliferative and alkylating properties of CEUs and Oxas on B16F0 melanoma 
cells. 
Compound Structure 
GI50 
(μM) 
-tubulin 
alkylation 
Microtubule 
structure 
DMSO 
 
  
  
ICEU 
N-(4-iodophenyl)- 
N’-(2-chloroethyl)urea 
 
10.6   
IOxa 
N-(4-iodophenyl)- 
4,5-dihydrooxazol-2-
amine 
 
2.9  
 
tBCEU 
N-(4-tertbutylphenyl)- 
N’-(2-chloroethyl)urea 
 
13.1 
  
tBOxa 
N-(4-tertbutylphenyl)- 4,5-
dihydrooxazol-2-amine 
 
7.1 
 
 
Compound Structure GI50 Prohibitin alkylation 
cHCEU 
N-(4-cyclohexylphenyl)- 
N’-(2-chloroethyl)urea 
 
17.0 
 
 
cHOxa 
N-(4-cyclohexylphenyl)- 
4,5-dihydrooxazol-2-
amine 
 
7.2   
GI50: drug concentration inhibiting 50% of cell growth; -tubulin alkylation: determined by 
western blot in B16F0 cells treated or not (DMSO) for 24 hours at 5-10 x GI50 drug 
concentration; Microtubule structure: visualised by immunofluorescence in B16F0 cells 
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treated or not (DMSO) for 24 hours at one GI50 drug concentration; prohibitin alkylation: 
determined by 2D western blot in B16F0 cells treated or not for 24 hours at a 5-10 x GI50 drug 
concentration. Arrows indicate the native form of the protein, asterisks indicate the alkylated 
form of the protein. 
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